Molecular Regulation of Apoprotein B Degradation

载脂蛋白 B 降解的分子调控

基本信息

项目摘要

DESCRIPTION (provided by applicant): This is a renewal application to continue studies on the molecular regulation of apoprotein B (apoB) degradation. ApoB is the predominant protein component of the atherogenic lipoproteins. Thus, knowledge of the regulation of the assembly and secretion of apoB-lipoproteins is not only of fundamental interest, but is also medically relevant. An important control of the net secretion of apoB from cells of hepatic origin is the level of its pre-secretory degradation, one of the many unusual features of the biosynthesis and assembly of apoB into lipoprotein particles. We have recently established powerful cell-free systems to complement studies in cultured cells and animal models to identify and investigate the molecular factors that target apoB to degradation by proteasomal and non-proteasomal mechanisms as well as those that mediate apoB exit from the ER as part of a lipoprotein particle. The application is divided into 3 proposed aims: Aim 1 is to determine the spectrum of factors regulating the proteasome-mediated ER-associated degradation (ERAD) of apoB. We have previously established that cytosolic Hsp70 and Hsp90 promote ERAD of apoB and propose that known Hsp70 and Hsp90 co-chaperones and accessory factors also play important roles. Aim 2 is to determine the role of oxidant stress in the post-ER, non-proteasomal degradation of apoB induced by n-3 fatty acids. N-3 fatty acids are known hypolipidemic agents and we have recent data that in hepatic cells they stimulate a post-ER, non-proteasomal, degradative pathway (with remarkable similarity to the one induced by insulin) that is blocked by anti-oxidants. The molecular characteristics of n-3-stimulated apoB degradation, particularly with regard to oxidant stress, and its relationship to the insulin-stimulated process, will be tested in cell culture systems and in 2 recently described mouse models of human diseases, one of familial combined hyperlipidemia (and which has increased hepatic antioxidant levels) and one of insulin resistance (the Akt2 KO mouse). Aim 3 is to determine the factors regulating the ER-exit of apoB-containing lipoproteins. Based on classical studies of protein trafficking, the large size and other properties of apoB lipoproteins make it likely that there are novel features that drive their packaging and exit from the ER. Using cell-free model systems (established, to our knowledge, for the first time for this purpose), and hepatic cells, we will identify the molecular characteristics of the ER-exit process.
描述(申请人提供):这是一个续期申请,以继续研究载脂蛋白B(ApoB)降解的分子调控。载脂蛋白B是致动脉粥样硬化脂蛋白的主要蛋白质组分。因此,了解载脂蛋白B-脂蛋白的组装和分泌的调节不仅具有基本意义,而且具有医学意义。肝来源细胞的载脂蛋白B净分泌的一个重要控制因素是其分泌前降解的水平,这是载脂蛋白B生物合成和组装成脂蛋白颗粒的许多不寻常特征之一。我们最近已经建立了强大的无细胞系统来补充在培养细胞和动物模型中的研究,以确定和研究靶向载脂蛋白B通过蛋白酶体和非蛋白酶体机制降解的分子因素,以及那些介导载脂蛋白B作为脂蛋白颗粒的一部分从内质网退出的分子因素。应用分为3个拟议的目的:目的1是确定调节蛋白酶体介导的内质网相关降解(ERAD)载脂蛋白B的因子的谱。我们已证实胞内Hsp70和Hsp90促进apoB的ERAD,并提出已知的Hsp70和Hsp90共伴侣和辅助因子也起重要作用。目的2确定氧化应激在n-3脂肪酸诱导的内质网后非蛋白酶体降解载脂蛋白B中的作用。N-3脂肪酸是已知的降血脂药物,我们最近的数据表明,在肝细胞中,它们刺激ER后的、非蛋白酶体的降解途径(与胰岛素诱导的途径非常相似),该途径被抗氧化剂阻断。N-3刺激的载脂蛋白B降解的分子特征,特别是关于氧化应激,及其与胰岛素刺激过程的关系,将在细胞培养系统和最近描述的两种人类疾病的小鼠模型中进行测试,其中一种是家族性混合性高脂血症(并增加了肝脏抗氧化水平),另一种是胰岛素抵抗(Akt2 KO小鼠)。目的3是确定调控载脂蛋白内质网退出的因素。基于蛋白质转运的经典研究,apoB脂蛋白的大小和其他性质使其有可能存在新的特征,从而驱动其包装和退出内质网。使用无细胞模型系统(据我们所知,这是第一次为此目的而建立)和肝细胞,我们将识别ER退出过程的分子特征。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward A Fisher其他文献

Technology Insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging
技术洞察:利用磁共振成像靶向生物分子以评估高危动脉粥样硬化斑块
  • DOI:
    10.1038/ncpcardio0013
  • 发表时间:
    2004-11-01
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Michael J Lipinski;Valentin Fuster;Edward A Fisher;Zahi A Fayad
  • 通讯作者:
    Zahi A Fayad
Summing up
加起来
  • DOI:
    10.1007/bf00871232
  • 发表时间:
    1947
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Edward A Fisher
  • 通讯作者:
    Edward A Fisher
Rapid regression of atherosclerosis: insights from the clinical and experimental literature
动脉粥样硬化的快速消退:来自临床和实验文献的见解
  • DOI:
    10.1038/ncpcardio1086
  • 发表时间:
    2008-02-01
  • 期刊:
  • 影响因子:
    44.200
  • 作者:
    Kevin Jon Williams;Jonathan E Feig;Edward A Fisher
  • 通讯作者:
    Edward A Fisher

Edward A Fisher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward A Fisher', 18)}}的其他基金

Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretion
控制肝脏apoB-Lp脂质负荷和分泌的新调控机制
  • 批准号:
    10628991
  • 财政年份:
    2023
  • 资助金额:
    $ 2.8万
  • 项目类别:
Atherosclerosis core
动脉粥样硬化核心
  • 批准号:
    10628989
  • 财政年份:
    2023
  • 资助金额:
    $ 2.8万
  • 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
  • 批准号:
    10616527
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
  • 批准号:
    10424901
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
  • 批准号:
    9209582
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
  • 批准号:
    10424904
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
  • 批准号:
    10616525
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
  • 批准号:
    10424900
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
  • 批准号:
    10616536
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
  • 批准号:
    9925242
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:

相似海外基金

Apolipoprotein B and associated proteins in the etiology of Alzheimer's disease: A Tau-specific association with Alzheimer pathophysiology.
阿尔茨海默病病因中的载脂蛋白 B 和相关蛋白:与阿尔茨海默病病理生理学的 Tau 特异性关联。
  • 批准号:
    444020
  • 财政年份:
    2021
  • 资助金额:
    $ 2.8万
  • 项目类别:
    Operating Grants
A whole-animal small molecule screen to identify and characterize modifiers of Apolipoprotein B
用于识别和表征载脂蛋白 B 修饰物的全动物小分子筛选
  • 批准号:
    10261421
  • 财政年份:
    2020
  • 资助金额:
    $ 2.8万
  • 项目类别:
A whole-animal small molecule screen to identify and characterize modifiers of Apolipoprotein B
用于识别和表征载脂蛋白 B 修饰物的全动物小分子筛选
  • 批准号:
    10460567
  • 财政年份:
    2020
  • 资助金额:
    $ 2.8万
  • 项目类别:
In vivo HTS assay for novel modulators of Apolipoprotein B
载脂蛋白 B 新型调节剂的体内 HTS 测定
  • 批准号:
    10398022
  • 财政年份:
    2018
  • 资助金额:
    $ 2.8万
  • 项目类别:
In vivo HTS assay for novel modulators of Apolipoprotein B
载脂蛋白 B 新型调节剂的体内 HTS 测定
  • 批准号:
    10502731
  • 财政年份:
    2018
  • 资助金额:
    $ 2.8万
  • 项目类别:
In vivo HTS assay for novel modulators of Apolipoprotein B
载脂蛋白 B 新型调节剂的体内 HTS 测定
  • 批准号:
    9976330
  • 财政年份:
    2018
  • 资助金额:
    $ 2.8万
  • 项目类别:
In vivo HTS assay for novel modulators of Apolipoprotein B
载脂蛋白 B 新型调节剂的体内 HTS 测定
  • 批准号:
    9788423
  • 财政年份:
    2018
  • 资助金额:
    $ 2.8万
  • 项目类别:
The Role of Sortilin in the Regulation of Apolipoprotein B Secretion from the liver and heart
分拣蛋白在调节肝脏和心脏载脂蛋白 B 分泌中的作用
  • 批准号:
    9329077
  • 财政年份:
    2017
  • 资助金额:
    $ 2.8万
  • 项目类别:
Translational Control of Apolipoprotein B mRNA
载脂蛋白 B mRNA 的翻译控制
  • 批准号:
    41858-2012
  • 财政年份:
    2016
  • 资助金额:
    $ 2.8万
  • 项目类别:
    Discovery Grants Program - Individual
Translational Control of Apolipoprotein B mRNA
载脂蛋白 B mRNA 的翻译控制
  • 批准号:
    41858-2012
  • 财政年份:
    2015
  • 资助金额:
    $ 2.8万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了